Ir
Non verificato

Ironwood Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network
16/10/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
Mercato del lavoro
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
1.00
03/09/2026
Eventi
Web e Social Network
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
1.00
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
1.00
30/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
1.00
28/05/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Eventi
Fiere
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
1.00
27/05/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
1.00
07/05/2026
Web e Social Network
Telefonia e Varie
Industria
Mercato azionario
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
1.00
30/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0